Clinical investigation
Thyroid
The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea

https://doi.org/10.1016/j.ijrobp.2005.12.010Get rights and content

Purpose: To determine the role of adjuvant external-beam radiotherapy (EBRT) in the management of patients with well-differentiated thyroid cancer invading the trachea.

Methods and Materials: Of 1,098 thyroid cancer patients, 68 (6%) were found to have tracheal invasion, and they all received “shave” excision of the tracheal cartilage. Among them, 12 patients had no postoperative residuum, 43 patients had microscopic residuum, and 13 patients had macroscopic residuum. All patients were divided into two groups according to treatment modality with or without EBRT; (1) the control group (n = 43) and (2) the EBRT group (n = 25).

Results: The locoregional recurrence rate for EBRT patients was much lower than that of control patients (51% for the control group vs. 8% for the EBRT group) (p < 0.01). The 10-year local progression-free survival rate for the EBRT group was significantly better than that of the control group (89% in the EBRT group vs. 38% in the control group) (log–rank, p < 0.01). The use of adjuvant EBRT after conservative surgery was an independent prognostic factor in univariate and multivariate analyses.

Conclusions: External-beam radiotherapy was found to be effective, particularly in patients with thyroid cancer invading the trachea with microscopic or gross residuum after conservative surgery.

Introduction

Despite the proximity of the thyroid gland to the upper aerodigestive tract, thyroid cancer only rarely invades the adjacent structures, such as the larynx, trachea, or cervical esophagus (1, 2). The prevalence of airway invasion by well-differentiated thyroid cancer reportedly ranges from 1% to 13% (3). However, airway invasion is an important clinical problem when locally advanced thyroid cancer involves the laryngotracheal airway. Although surgical resection is the cornerstone of treatment for such patients, there is considerable controversy regarding the extent of surgery and the appropriate postoperative adjuvant treatment. If the cancer is either close to or invading a segment of the upper aerodigestive tract, the decision to remove the structures is a difficult therapeutic dilemma because of the generally indolent nature of most thyroid cancers. If technically feasible, tracheal resection by means of a sleeve or window is the preferred treatment for patients with intraluminal invasion (4). Alternately, “shave” resection of all gross tumors involving the trachea might be possible unless well-differentiated thyroid cancer infiltrates the tracheal perichondrium (5, 6). In fact, a few experts have advocated for a conservative “shave” procedure that might be a better treatment in the case of limited involvement of the trachea, because this approach shows a lower morbidity and a similar survival rate when compared with “en bloc” resection of the tumor and adjacent vital structures (7, 8).

Several investigators, however, have reported that tracheal invasion is a significant and independent negative prognostic factor for survival when surgery alone is used (5, 7, 9). It is well known that patients with locally advanced thyroid cancer with tracheal invasion have a higher recurrence rate, a higher incidence of cervical node metastases, and a higher mortality rate (4, 7, 8, 9, 10). Nonetheless, the role of adjuvant therapy for such patients has not yet been clearly established in the literature. Although postoperative radioiodine ablation with thyroid-stimulating hormone (TSH) suppression is imperative after surgical resection of locally advanced thyroid cancer (11), external-beam radiotherapy (EBRT) has not been widely used even in patients with microscopic or small gross residual disease after surgical resection. Until recently, the beneficial role of EBRT had not been investigated systemically, particularly among the subsets of patients with tracheal invasion by thyroid carcinoma. The aim of the present study was to evaluate the potential role of postoperative adjuvant EBRT in the management of patients treated with conservative surgery for locally advanced thyroid cancer invading the tracheal cartilage.

Section snippets

Patients and treatments

Between 1986 and 1997, 1,098 patients with well-differentiated thyroid cancers were treated surgically at the Yonsei Cancer Center, Yonsei University, College of Medicine (Seoul, Korea). Among them, 75 (7%) were found to have tracheal invasion at the time of admission. Of these, 2 patients with follicular carcinomas and 1 patient with medullary carcinoma were excluded to make the study population more homogeneous. Four patients who had either metastasis to the mediastinal lymph nodes or distant

Clinical profiles

To determine the role of adjuvant EBRT given after tracheal resection or tracheal cartilage “shave,” we divided all patients into two groups according to the administration of external radiotherapy: (1) the control group (n = 43) and (2) the EBRT group (n = 25). Clinical profiles of both groups are listed in Table 1. There were significant and marginal differences in the sex and age distribution of the two groups, respectively. The serum levels of thyroglobulin were similar between the two

Discussion

This study was undertaken to examine the role of adjuvant EBRT administered after “shave” excision of the tracheal cartilage in the management of patients with locally advanced thyroid carcinoma adhering to or invading the trachea. Clinically, approximately 7% of 1,098 patients undergoing surgery for thyroid cancer were found to have tracheal invasion at the time of initial diagnosis in our series. Our data also demonstrated that patients who received EBRT had a lesser likelihood of local

References (20)

There are more references available in the full text version of this article.

Cited by (61)

  • Trends in Adjuvant External Beam Radiation Therapy for Nonanaplastic Thyroid Cancer in California, 2003-2017

    2022, Endocrine Practice
    Citation Excerpt :

    Previous studies have found no significant improvement in the locoregional control after EBRT, likely because of the inclusion of patients with low- and intermediate-risk disease.1,2 EBRT appears to improve local control and survival in patients with unresectable disease, in patients with gross residual disease or positive margins after surgery,3-6 and in older patients with high-risk disease.7-11 Because EBRT carries significant treatment-related morbidity and makes future neck reoperations more hazardous, it is mainly considered in patients who have already undergone multiple reoperations for locally recurrent disease and in whom additional reoperations would result in an unacceptable high risk of morbidity.12

  • Combining radionuclide therapy with radiotherapy

    2022, Nuclear Medicine and Molecular Imaging: Volume 1-4
  • External Beam Radiation Therapy in pT4 Well-Differentiated Thyroid Cancer: A Population-Based Study of 405 Patients

    2021, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    Currently, the American Thyroid Association recommends consideration of EBRT for patients with gross residual disease, but the AHNS recommends consideration of EBRT for patients with gross residual disease, except in cases where the patient is age < 45 years and has RAI-avid disease.4,5 EBRT is also recommended in cases where there is a high likelihood of microscopic residual disease and low probability of response to RAI or in the case of aerodigestive organ involvement where EBRT may facilitate organ preservation and avoid morbid surgical intervention.4,5,22,23 EBRT is discouraged in cases of complete resection.4

  • External Beam Radiotherapy for Thyroid Malignancy

    2021, Surgery of the Thyroid and Parathyroid Glands
View all citing articles on Scopus
View full text